Brief: Olema Oncology Advances Op-1250 Into Phase 2 Monotherapy Expansion In Patients With Er+/Her2- Advanced Breast Cancer
09/08/2022 23:13
Aug 9 (Reuters) - Olema Pharmaceuticals Inc OLMA.O :
* OLEMA ONCOLOGY ADVANCES OP-1250 INTO PHASE 2 MONOTHERAPY
EXPANSION IN PATIENTS WITH ER+/HER2- ADVANCED BREAST CANCER
Source text for Eikon: ID:nGNX6sh9ZP
Further company coverage: OLMA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Olema Pharmaceuticals
See all newsOlema Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Olema Pharmaceuticals Q2 net loss widens on higher clinical trial spending
Brief: Olema Pharmaceuticals Q2 Net Income USD -63.2 Million
Brief: Olema Oncology Announces Clinical Trial Collaboration And Supply Agreement With Bayer To Evaluate Op-3136 In Combination With Nubeqa® (Darolutamide) In Metastatic Castration-Resistant Prostate Cancer
Olema Pharmaceuticals Q1 net loss widens on higher R&D costs